



LIBERTAS
JUSTITIA
VERITAS

Purification and identification of the myostatin inhibitory peptides from mealworm (*Tenebrio molitor* larvae) protein hydrolysate in C2C12 cells


Eunyoung Oh* ^{1,2}, Hyeon Soo Kim³, Yookyung Kim ¹

¹ Department of Human Ecology (Food Science and Nutrition), Graduate School, Korea University, Seoul 136-701, Republic of Korea

²Interdisciplinary Program in Sustainable Living System, Graduate School, Korea University, Seoul 136-701, Republic of Korea

³Department of Anatomy, Korea University College of Medicine, Korea University, Seoul 136-701, Republic of Korea

Graphical abstract



Results




Figure 1. Anion exchange chromatograph of MT




Figure 2. Reverse phase chromatograph of D1




Figure 3. (A) Heat-map analysis of amino acid, BCAAs ratio of (B) D fractions, and (C) C fractions

Introduction and Objective

Mealworms (*Tenebrio molitor* larvae) are considered a highly nutritious and sustainable protein source. **Bioactive peptides** produced from protein hydrolysis have recently gained interest as alternative chemotherapeutic agents due to their potential to improve physiological activities. Muscle atrophy, wasting or loss of muscle mass, is a prevalent problem limiting physical activity and reducing the overall quality of life. Nonetheless, there are currently few investigations on natural agents preventing **muscle atrophy**. In this study, two potential peptides, Phe-Asp-Lys-Tyr (**FDKY**) and Phe-Asp-Arg-Leu (**FDRL**), were purified and identified from mealworm protein hydrolysate (MPH), and their inhibitory potentials of **myostatin**, a major negative regulator of skeletal muscle, in C2C12 cells were determined.

Keywords: Mealworm, Bioactive peptides, Muscle atrophy, Myostatin

Materials and Methods




Table 1. Best peptide sequence

No.	Best Sequence	Modifications	Original protein
1	GSYSLVDPDGTRR		larval cuticle protein A3A-like
2	SYSLVDPDGTRR		larval cuticle protein A3A-like
3	NGFNAVVR	Deamidated(N)@1, Deamidated(N)@4	hypothetical protein GEV33_008419
4	FDKY		86 kDa early-staged encapsulation inducing protein
5	FDRL		86 kDa early-staged encapsulation inducing protein
6	SNGFGEIK	Deamidated(N)@2	86 kDa early-staged encapsulation inducing protein
7	GVQDPLTGDKV		hypothetical protein GEV33_008419

Patent pending




Figure 4. Effects of (A) D fractions and (B) MT and D1 on myostatin promoter activity

Figure 5. Effects of (A) C fractions and (B) D1 and C3 on myostatin promoter activity

Figure 6. Effects of identified peptides on myostatin promoter activity




Figure 7. Effects of dose-dependent induction of (A) #4 (FDKY) and (B) #5 (FDRL) on myostatin promoter activity

Figure 8. Effects of #4 (FDKY) and #5 (FDRL) on myostatin mRNA expression levels

MPI: mealworm protein isolate; MPH: mealworm protein hydrolysate; MT: mealworm protein hydrolysate fraction > 10kDa; D1-4: anion-exchange chromatography fractions of MT; C1-5: reverse-phase chromatography fractions of D1

a-d Different superscripts indicate significant differences according to Duncan's multiple range test ($p < 0.05$).

Statistical significance was determined by Student's t -test compared to the control (CON; no treatment) group (* $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$).

Statistical significance was determined by Student's t -test, comparing to an upper-level fraction (* $p < 0.05$, ** $p < 0.01$).

Summary and Conclusions

- D1 and C3, which have the most significant potential for myostatin inhibition in each fractionation step, had the highest branched chain to total amino acid ratios.
- Among all the peptides, only the treatment of FDKY and FDRL significantly lowered the luciferase activity compared to the control group (no treatment) in a dose-dependent manner. FDKY treatment also decreased myostatin mRNA expression levels compared to the control group.
- The bioactive peptides from MPH could be an attractive natural agent that can be used as a drug or functional food ingredient to prevent muscle atrophy.

Acknowledgement

This research was supported by the National Institute of Agricultural Sciences, RDA, Republic of Korea (Project No.PJ01591202).

AUTHOR INFORMATION

- Ph.D Candidate **Eunyoung Oh**: oheuy0725@korea.ac.kr
- (Correspondence) Professor **Yookyung Kim**: yookyung_kim@korea.ac.kr



IPS 2023